Geron Corporation (NASDAQ:GERN)’s EVP Melissa Kelly Behrs sold 4826 shares of GERN in a transaction dated on May 29, 2014. Geron Corporation (NASDAQ:GERN) shares were sold at an average price of $2.10 for total worth of $10,134.60. Geron Corporation (NASDAQ:GERN) weekly performance is 1.46%. On last trading day company shares ended up $2.08. Analysts mean target price for the company is $2.00. Geron Corporation (NASDAQ:GERN) distance from 50-day simple moving average (SMA50) is 4.74%.
Acceleron Pharma Inc. (NASDAQ:XLRN) Director Jean George sold 215,644 shares of Acceleron Pharma stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $42.86, for a total value of $9,242,501.84. Acceleron Pharma Inc. (NASDAQ:XLRN) shares fell -1.75% in last trading session and ended the day on $29.68. XLRN return on assets is -37.40%.Acceleron Pharma Inc. (NASDAQ:XLRN) quarterly performance is -36.76%.
Osiris Therapeutics Inc. (NASDAQ:OSIR) CFO Philip Jacoby, Jr. unloaded 15,947 shares of the company’s stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $15.43, for a total value of $246,062.21. Following the completion of the sale, the chief financial officer now directly owns 12,500 shares in the company, valued at approximately $192,875. Osiris Therapeutics, Inc. (NASDAQ:OSIR) shares moved down -2.22% in last trading session and was closed at $15.39, while trading in range of $15.01 – $16.00. Osiris Therapeutics, Inc. (NASDAQ:OSIR) year to date (YTD) performance is -4.29%.
BioSpecifics Technologies Corp. (NASDAQ:BSTC) Director Henry Morgan sold 20,000 shares of the stock on the open market in a transaction dated Thursday, May 29th. The stock was sold at an average price of $27.03, for a total value of $540,600.00. Following the completion of the transaction, the director now directly owns 37,193 shares in the company, valued at approximately $1,005,327. BioSpecifics Technologies Corp. (NASDAQ:BSTC) ended the last trading day at $26.98. Company weekly volatility is calculated as 3.03% and price to cash ratio as 15.26.BioSpecifics Technologies Corp. (NASDAQ:BSTC) showed a positive weekly performance of 2.66%.